U.S. markets open in 4 hours 29 minutes

CureVac N.V. (CVAC)

NasdaqGM - NasdaqGM Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
17.30+1.85 (+11.97%)
Al cierre: 04:00PM EDT
17.30 0.00 (0.00%)
Antes de la apertura del mercado: 04:42AM EDT

CureVac N.V.

Friedrich-Miescher-Strasse 15
Tübingen 72076
Germany
49 7071 9883 0
https://www.curevac.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo764

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Franz-Werner Haas L.L.M., LLD, Ph.D., LL.M.CEO & Member of Management Board628.26kN/D1970
Mr. Pierre Kemula B.Sc.MD, CFO & Member of Management Board611.16kN/D1975
Dr. Igor Splawski M.Sc., Ph.D.Chief Scientific Officer & Member of Management Board411.95kN/D1969
Dr. Antony Blanc Ph.D.MD, Chief Bus. Officer, Chief Commercial Officer & Member of Management Board372.57kN/D1970
Dr. Klaus Edvardsen M.D., Ph.D.MD, Chief Devel. Officer & Member of Management BoardN/DN/D1962
Mr. Malte Greune Ph.D.COO & Member of Management BoardN/DN/D1965
Dr. Sarah FakihVP Corp. Communications & Investor RelationsN/DN/DN/D
Mr. Thorsten SchullerHead of Corp. CommunicationsN/DN/DN/D
Slavica Stevanovic-HeckHead of HRN/DN/DN/D
Dr. Patrick BaumhofSr. VP of TechnologyN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2020 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.

Gestión corporativa

La calificación ISS Governance QuickScore de CureVac N.V. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.